Enlimomab |
|
Phase Ⅲ |
Boehringer Ingelheim |
Stroke, Autoimmune diseases, Diabetes, Graft versus host disease, Intracranial thrombosis, Rejection of liver transplantation, Myocardia ischemia, Rheumatoid arthritis (RA), Burns, Asthma, Rejection of renal transplantation |
Details
|
GI-270384X |
GI-270384X; GI-270384 |
Phase Ⅱ |
GlaxoSmithKline |
Inflammatory bowel disease |
Details
|
BAY-Z-9700 |
BAY-Z-9700 |
Phase Ⅰ |
Bayer |
Rhinitis, Asthma |
Details
|
AIC-100 |
AIC-100,AIC100 |
Phase Ⅰ |
AffyImmune Therapeutics |
Thyroid cancer |
Details
|
RhinoRx (Planet Biotechnology) |
|
Preclinical |
Planet Biotechnology |
HRV infection |
Details
|
ICM-3 |
ICM-3 |
Phase Ⅱ |
ICOS Corporation |
Psoriasis |
Details
|
tICAM-1-453 (Bayer) |
|
Phase Ⅰ |
Bayer |
HRV infection |
Details
|
Coxsackievirus A21 (Viralytics) |
CVA-21; V-937 |
Phase Ⅱ |
Viralytics |
Melanoma |
Details
|
Tyroserleutide |
CMS-024; YSL; alpha-BCP[7-9],CMS024 |
NDA Filing |
China Medical System Holdings |
Hepatocellular carcinoma (HCC) |
Details
|
Bersanlimab |
BI-505 |
Phase Ⅱ |
BioInvent International |
Multiple myeloma (MM) |
Details
|
Alicaforsen sodium |
AP-1007; AP-1431; AP-1450; AP-1451; ISIS-2302 |
NDA Filing |
Ionis Pharmaceuticals, Atlantic Healthcare |
Ulcerative colitis, Pouchitis, Inflammatory bowel disease |
Details
|
DZ-13 |
DZ-13; DZ13 |
Phase Ⅰ |
University of New South Wales, Royal Prince Alfred Hospital |
Basal cell carcinoma (BCC), Metastatic melanoma |
Details
|